Lung Cancer News and Research

Latest Lung Cancer News and Research

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Neutrophils play an unexpected role in mediating insulin resistance

Researchers at the University of California, San Diego School of Medicine say neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance - the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.

6 Aug 2012

Diabetes impairs women’s sex life

Women with diabetes are less likely to find sex satisfying than those without the condition, despite having similar levels of interest and engagement in sexual activity, show study findings.

3 Aug 2012

Six hospitals join CoC ProvenCare Lung Cancer Collaborative

Six more hospitals have joined a national pilot study already under way to promote evidence-based evaluation and treatment standards for patients with non-small cell lung cancer (NSCLC). Patients with this type of lung cancer are also candidates for an operation called "lung resection."

2 Aug 2012

Serving size in the eye of the beholder

Canadian study findings suggest that many people overestimate the size of one serving of food and may overeat as a result.

2 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Life Technologies second quarter revenue increases 1% to $950 million

Life Technologies Corporation today announced results for its second quarter ended June 30, 2012.

31 Jul 2012

E-nose detects malignant mesothelioma

Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

31 Jul 2012

EPHA3 mutations may be important drivers of lung cancers

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors.

31 Jul 2012

Conception plans miscarry with sperm DNA damage

Sperm with damaged DNA are more likely to cause spontaneous pregnancy loss, report researchers.

30 Jul 2012

Antioxidants and pancreatic cancer risk: an interview with Dr Andrew Hart

The antioxidants that we mainly looked at were selenium, vitamin C and vitamin E. They are chemicals which inactivate pro-oxidants or free radicals. Smoking and normal metabolism can lead to the production of free radicals.

30 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Steak and ticks: A potentially life-threatening experience

Tick bites can trigger a severe, delayed allergic reaction to red meat, suggest findings published in the Journal of General Internal Medicine.

27 Jul 2012

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012